Skip to main content

ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on May 28, 2025.

via HealthDay

WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a study scheduled to be presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Noting that obesity is a risk factor for cancer development, Lucas Mavromatis, from the NYU Grossman School of Medicine in New York City, and colleagues examined whether GLP-1 RAs reduce the risk for obesity-related cancer in adults with diabetes and obesity compared to weight-neutral DPP-4 inhibitors. Data were included for 85,015 adults with a body mass index ≥30 kg/m2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023. Patients prescribed GLP-1 RAs were matched 1:1 on propensity score with those prescribed DPP-4 inhibitors.

The researchers found that the risks for obesity-related cancers and all-cause death were lower during a mean follow-up of 3.9 years (adjusted hazard ratios, 0.93 and 0.92, respectively) in association with GLP-1 RA versus DPP-4 inhibitor use. Protective associations were seen between GLP-1 RA use and colon and rectal cancers.

"Our results suggest [GLP-1 RAs] may modestly cut the chance of developing certain cancers -- especially cancers of the colon and rectum -- and reduce rates of death due to all causes," Mavromatis said in a statement. "These data are reassuring, but more studies are required to prove causation."

One author disclosed ties to the biopharmaceutical industry.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Cannabis Use Disorder Linked to Increased Risk for Oral Cancer

FRIDAY, Aug. 1, 2025 -- Cannabis use disorder (CUD) is associated with an increased risk for oral cancer, according to a study published in the September issue of Preventive...

Racialized Economic Segregation Linked to Advanced Cancer Diagnosis

FRIDAY, Aug. 1, 2025 -- People living in racially and economically segregated neighborhoods are more likely to be diagnosed with advanced-stage breast and cervical cancer...

New Subtype of Diabetes Identified in Sub-Saharan Africans, Black Americans

FRIDAY, Aug. 1, 2025 -- A new diabetes subtype has been identified in Sub-Saharan Africans and Black Americans, according to a study published online July 21 in The Lancet...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.